PAK6 and cancer: In the current study we ask whether downstream substrate specificity is conserved among the type II PAKs, whether a cancer-associated mutation that occurs in the type II PAK autoinhibitory region can activate PAK6, and whether co-crystallography might aid drug discovery for type II PAKs.